GO:0071774 response to fibroblast growth factor: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071774 describes any cellular or organismal change caused by a fibroblast growth factor (FGF) stimulus, including changes in movement, secretion, enzyme production, and gene expression.
• The FGF family comprises 22 ligands in humans that signal through four FGF receptor tyrosine kinases (FGFR1-4) and a co-receptor, Klotho, to regulate development, metabolism, and stress responses.
• FGF21 is a major endocrine FGF that coordinates the adaptive response to nutritional challenges such as fasting, ketogenic diets, and protein restriction.
• FGF15/19 (mouse FGF15, human FGF19) is induced in the intestine by bile acids and regulates bile acid synthesis, lipid metabolism, and energy homeostasis.
• Dysregulated FGF signaling is implicated in metabolic disorders including obesity, insulin resistance, and diabetes mellitus.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential tools for dissecting the causal roles of FGF pathway components in health and disease.
Description
The Gene Ontology (GO) term GO:0071774, response to fibroblast growth factor, defines the cellular and organismal processes triggered by fibroblast growth factor (FGF) stimulation. FGFs constitute a large family of signaling molecules that regulate diverse biological functions, including embryonic development, tissue repair, metabolic homeostasis, and stress responses. The response to FGF involves ligand binding to cell-surface FGF receptors (FGFRs), activation of intracellular signaling cascades, and subsequent changes in gene expression, enzyme activity, secretion, and cell movement. This term is critical for researchers studying development, metabolism, and disease because FGF signaling is frequently dysregulated in cancer, metabolic disorders, and mitochondrial diseases. Understanding the precise molecular events and regulatory mechanisms of FGF responses enables the identification of therapeutic targets and the design of experimental models to test causal hypotheses.
response to fibroblast growth factor At A Glance
| GO ID | GO:0071774 |
|---|---|
| GO term | response to fibroblast growth factor |
| Ontology | biological_process |
| Synonym | response to FGF stimulus; response to fibroblast growth factor stimulus |
| Major function | Mediates cellular and organismal changes in response to FGF ligands, including alterations in gene expression, metabolism, secretion, and cell movement. |
| Key ligands | FGF1, FGF21, FGF15/19, and other FGF family members. |
| Key receptors | FGFR1-4 tyrosine kinases; co-receptor Klotho for endocrine FGFs. |
| Associated diseases | Obesity, insulin resistance, diabetes mellitus, mitochondrial myopathy, and cancer. |
What Is GO:0071774?
GO:0071774, response to fibroblast growth factor, is defined as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fibroblast growth factor stimulus. This term encompasses the immediate signaling events following FGF receptor activation as well as the downstream transcriptional and metabolic adaptations that occur in response to FGF ligands.
Why Is response to fibroblast growth factor Important in Cell Biology?
GO:0071774 is important because FGF signaling is a central node in development, metabolism, and stress responses, and its dysregulation contributes to major human diseases. FGF21, for example, is a stress-induced hormone that drives adaptive responses to nutritional challenges and mitochondrial dysfunction. FGF15/19 regulates bile acid and lipid metabolism, and its impairment is linked to insulin resistance and diabetes. Understanding the response to FGF at the molecular level provides insights into disease mechanisms and identifies potential therapeutic targets.
• FGF signaling controls embryonic development and organogenesis.
• FGF21 mediates adaptive responses to fasting, ketogenic diets, and protein restriction.
• FGF21 is induced by mitochondrial stress and drives local and systemic stress responses.
• FGF15/19 regulates bile acid synthesis and lipid metabolism.
• Impaired FGF21 is associated with visceral adiposity and insulin resistance in diabetes mellitus.
• Klotho proteins act as co-receptors for endocrine FGFs and are involved in aging and kidney disease.
• FGF1 is a metabolic messenger that regulates glucose homeostasis.
• Dysregulated FGF signaling is implicated in obesity and obesity resistance.
• FGF pathway components are potential targets for therapeutic intervention in metabolic diseases.
• CRISPR screening can identify novel regulators of FGF responses.
What Happens During response to fibroblast growth factor?
Ligand binding and receptor activation
In simple terms: FGF molecules bind to receptors on the cell surface, switching them on.
The response to FGF begins when an FGF ligand binds to a fibroblast growth factor receptor (FGFR) on the cell surface. This binding induces receptor dimerization and autophosphorylation of tyrosine kinase domains, creating docking sites for intracellular signaling proteins. For endocrine FGFs such as FGF21 and FGF15/19, the co-receptor Klotho (alpha-Klotho or beta-Klotho) is required for high-affinity binding and signaling.
Intracellular signaling cascades
In simple terms: Activated receptors trigger a chain of signals inside the cell.
Activated FGFRs phosphorylate downstream targets including FRS2, which recruits GRB2 and SOS to activate the RAS-MAPK pathway, and PLCgamma to produce IP3 and DAG, leading to calcium release and PKC activation. These cascades alter gene expression, enzyme activity, and cytoskeletal dynamics, producing the cellular changes characteristic of GO:0071774.
Transcriptional and metabolic reprogramming
In simple terms: The cell changes which genes are turned on and how it uses energy.
FGF signaling induces transcription factors such as EGR1 and c-FOS, which regulate genes involved in proliferation, differentiation, and metabolism. In metabolic tissues, FGF21 induces PGC-1alpha and UCP1, promoting energy expenditure and fatty acid oxidation. FGF15/19 suppresses CYP7A1, the rate-limiting enzyme in bile acid synthesis, thereby regulating bile acid and lipid homeostasis.
Systemic stress responses
In simple terms: FGFs can act as hormones that coordinate whole-body responses to stress.
FGF21 is secreted by the liver in response to fasting, ketogenic diets, and mitochondrial stress, acting on adipose tissue and the brain to regulate energy balance. In mitochondrial myopathy with mtDNA deletions, FGF21 drives local and systemic stress responses, serving as a biomarker and mediator of adaptation. FGF15/19 is induced in the intestine by bile acids and signals to the liver to modulate metabolism.
Feedback regulation and termination
In simple terms: The signal is turned off when it is no longer needed.
FGF signaling is attenuated by negative feedback mechanisms, including induction of Sprouty proteins and MAPK phosphatases, which inhibit RAS-MAPK signaling. Receptor internalization and degradation also terminate the response. Dysregulation of these feedback loops can lead to sustained FGF signaling, contributing to metabolic disorders and cancer.
Key Genes Involved in GO:0071774 response to fibroblast growth factor
The following genes and proteins are central to the response to fibroblast growth factor (GO:0071774), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGF1 | Prototypical FGF ligand; regulates cell proliferation and glucose homeostasis | Metabolic messenger; studied in diabetes and obesity |
| FGF21 | Endocrine FGF; mediates adaptive responses to fasting and mitochondrial stress | Biomarker and therapeutic target in metabolic diseases |
| FGF15/19 | Intestinal hormone regulating bile acid synthesis and lipid metabolism | Linked to insulin resistance and diabetes |
| FGFR1 | High-affinity receptor for FGF1 and other FGFs | Mediates developmental and metabolic FGF signaling |
| FGFR2 | Receptor tyrosine kinase for FGF ligands | Involved in development and cancer |
| FGFR3 | Receptor for FGFs in bone and cartilage | Mutations cause skeletal disorders |
| FGFR4 | Receptor for FGF19 in liver | Regulates bile acid synthesis |
| KLB (beta-Klotho) | Co-receptor for FGF21 and FGF15/19 | Essential for endocrine FGF signaling |
| KL (alpha-Klotho) | Co-receptor for FGF23 | Involved in phosphate homeostasis and aging |
| FRS2 | Adaptor protein docking to FGFR | Links FGFR to RAS-MAPK pathway |
| GRB2 | Adaptor protein in RAS-MAPK signaling | Propagates FGF signals |
| SOS1 | Guanine nucleotide exchange factor for RAS | Activates RAS downstream of FGFR |
| MAPK1 (ERK2) | Kinase in MAPK cascade | Transduces FGF signals to nucleus |
| EGR1 | Transcription factor induced by FGF signaling | Regulates FGF-responsive genes |
| CYP7A1 | Rate-limiting enzyme in bile acid synthesis | Suppressed by FGF15/19 |
| UCP1 | Uncoupling protein in brown adipose tissue | Induced by FGF21 to increase energy expenditure |
| PGC-1alpha (PPARGC1A) | Transcriptional coactivator of mitochondrial biogenesis | Mediates FGF21 effects on metabolism |
| SPRY2 | Sprouty protein; negative feedback regulator of FGF signaling | Attenuates RAS-MAPK pathway |
How Is response to fibroblast growth factor Regulated?
The response to fibroblast growth factor is tightly regulated at multiple levels. Ligand availability is controlled by transcriptional induction (e.g., FGF21 in response to fasting or mitochondrial stress) and by secretion. Receptor activation is modulated by co-receptors such as Klotho, which determine ligand specificity and tissue sensitivity. Intracellular signaling is attenuated by negative feedback loops involving Sprouty proteins and MAPK phosphatases, which prevent excessive pathway activation. Additionally, cross-talk with other signaling pathways, such as insulin and mTOR, fine-tunes the metabolic outcomes of FGF signaling.
response to fibroblast growth factor and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGF21 | Obesity, insulin resistance, diabetes mellitus | Knockout mouse, overexpression in liver |
| FGF15/19 | Metabolic syndrome, bile acid dysregulation | Intestinal-specific knockout, knock-in |
| KLB | Metabolic disorders, bile acid metabolism | Knockout cell lines, point mutation |
| FGFR1-4 | Cancer, skeletal disorders | Point mutation knock-in, overexpression |
| KL | Chronic kidney disease, aging | Knockout mouse, overexpression |
Metabolic disorders and diabetes
Dysregulated FGF21 signaling is associated with visceral adiposity and insulin resistance, representing a core defect in diabetes mellitus. FGF21 and GDF15 are stress-induced hormones that contribute to obesity resistance or susceptibility. FGF15/19 expression is altered in metabolic syndrome, affecting bile acid and lipid homeostasis.
Mitochondrial myopathy
In mitochondrial myopathy with mtDNA deletions, FGF21 is induced and drives local and systemic stress responses, serving as a diagnostic biomarker and mediator of metabolic adaptation.
Chronic kidney disease and aging
Klotho proteins, which act as co-receptors for endocrine FGFs, are involved in phosphate homeostasis and are downregulated in chronic kidney disease and aging, linking FGF signaling to these conditions.
Cancer
Aberrant FGF signaling, including FGFR mutations and amplifications, promotes tumor growth and survival in multiple cancers, making FGF pathway components targets for therapeutic intervention.
From response to fibroblast growth factor-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FGF21 mediate adaptive responses to fasting? | FGF21 knockout mouse |
| Is FGF15/19 required for bile acid feedback regulation? | FGF15/19 knockout or liver-specific FGFR4 knockout |
| What is the role of Klotho in FGF21 signaling? | KLB knockout cell lines |
| Does a specific FGFR mutation drive cancer? | Point mutation knock-in in cell lines |
| Can FGF21 overexpression improve metabolic parameters? | Transgenic overexpression in mouse liver |
| What genes regulate FGF21 expression? | CRISPR library screening |
How to Study the response to fibroblast growth factor Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify FGF-responsive genes |
| Phosphoproteomics | Phosphorylation of signaling proteins | Map FGFR downstream pathways |
| Western blot | Protein levels and activation states | Validate FGF signaling activation |
| ELISA | Secreted FGF21 or FGF15/19 levels | Biomarker assessment in metabolic studies |
| Metabolic flux analysis | Glucose and lipid metabolism | Assess FGF effects on energy homeostasis |
| CRISPR screening | Genes required for FGF response | Identify novel regulators |
| Immunofluorescence | Protein localization and cell morphology | Study FGF-induced changes |
Transcriptomic analysis (RNA-seq)
RNA sequencing measures global changes in gene expression following FGF stimulation, identifying transcriptional targets and pathways regulated by GO:0071774.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics quantifies protein abundance and phosphorylation events downstream of FGFR activation, revealing signaling networks and feedback mechanisms.
Metabolic assays
Measurements of glucose uptake, fatty acid oxidation, and bile acid levels assess the metabolic outcomes of FGF signaling in cells and animal models.
Imaging and reporter assays
Fluorescent reporters and live-cell imaging visualize FGF-induced changes in protein localization, secretion, and cell movement.
How CRISPR Can Be Used to Study GO:0071774 response to fibroblast growth factor
Knockout
CRISPR knockout of FGF pathway genes (e.g., FGF21, KLB, FGFR1) in cell lines or animal models abolishes specific responses, allowing researchers to test necessity. For example, FGF21 knockout mice display impaired adaptive responses to fasting.
Point Mutation
Introducing precise point mutations in FGFR or Klotho genes via CRISPR can mimic disease-associated variants or disrupt specific phosphorylation sites, enabling structure-function studies of FGF signaling.
Knock-in
Knock-in of tagged or reporter alleles (e.g., GFP-FGF21) allows real-time tracking of ligand expression, secretion, and localization in response to physiological stimuli.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of FGF21 or FGF15/19 can enhance signaling, providing gain-of-function models to study metabolic benefits and potential adverse effects.
How EDITGENE Supports response to fibroblast growth factor Research
Researchers studying response to fibroblast growth factor-related genes often need to determine whether a candidate gene is causally involved in FGF signaling, metabolic regulation, or disease progression. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation of FGF pathway components.
Contact EDITGENE today to design your custom CRISPR model for response to fibroblast growth factor research.
Frequently Asked Questions About response to fibroblast growth factor
What is GO:0071774?
GO:0071774 is the Gene Ontology term for response to fibroblast growth factor, describing any cellular or organismal change caused by an FGF stimulus.
What genes are involved in response to fibroblast growth factor?
Key genes include FGF1, FGF21, FGF15/19, FGFR1-4, KLB, KL, FRS2, and downstream signaling components like MAPK1.
What is the role of FGF21 in metabolism?
FGF21 is an endocrine hormone that mediates adaptive responses to fasting, ketogenic diets, and mitochondrial stress, regulating energy expenditure and glucose homeostasis.
How does FGF15/19 regulate bile acid synthesis?
FGF15/19 is induced by bile acids in the intestine and signals through FGFR4/KLB in the liver to suppress CYP7A1, the rate-limiting enzyme in bile acid synthesis.
What diseases are associated with impaired FGF signaling?
Impaired FGF signaling is linked to obesity, insulin resistance, diabetes mellitus, mitochondrial myopathy, chronic kidney disease, and cancer.
What is the difference between FGF21 and FGF1?
FGF21 is an endocrine FGF requiring Klotho co-receptors, while FGF1 is a prototypical paracrine/endocrine FGF that regulates cell proliferation and metabolism.
How can CRISPR be used to study FGF signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to test the causal role of FGF pathway genes in cellular and animal systems.
What are the main signaling pathways downstream of FGFR?
FGFR activation triggers RAS-MAPK, PI3K-AKT, PLCgamma-PKC, and STAT pathways, leading to changes in gene expression and metabolism.
Is FGF21 a biomarker for mitochondrial disease?
Yes, FGF21 is induced in mitochondrial myopathy with mtDNA deletions and serves as a diagnostic biomarker and mediator of stress responses.
What experimental models are used to study response to FGF?
Common models include knockout mice, cell lines with CRISPR edits, and overexpression systems for FGF ligands or receptors.
Conclusion
GO:0071774, response to fibroblast growth factor, encompasses the diverse cellular and systemic changes triggered by FGF ligands. From developmental signaling to metabolic adaptation and stress responses, FGF pathways are central to human health and disease. Continued research using CRISPR-based models and multi-omics approaches will further elucidate the mechanisms and therapeutic potential of FGF signaling.
References
- 1. Martínez-Garza Ú et al.. 2019. Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges.. Int J Mol Sci 20(19) PMID: 31546675
- 2. Kuro-O M. 2019. The Klotho proteins in health and disease.. Nat Rev Nephrol 15(1):27-44 PMID: 30455427
- 3. Keipert S et al.. 2021. Stress-induced FGF21 and GDF15 in obesity and obesity resistance.. Trends Endocrinol Metab 32(11):904-915 PMID: 34526227
- 4. Gasser E et al.. 2022. Metabolic Messengers: fibroblast growth factor 1.. Nat Metab 4(6):663-671 PMID: 35681108
- 5. Ornitz DM et al.. 2001. Fibroblast growth factors.. Genome Biol 2(3):REVIEWS3005 PMID: 11276432
- 6. Forsström S et al.. 2019. Fibroblast Growth Factor 21 Drives Dynamics of Local and Systemic Stress Responses in Mitochondrial Myopathy with mtDNA Deletions.. Cell Metab 30(6):1040-1054.e7 PMID: 31523008
- 7. Jain U et al.. 2025. Impaired Fibroblast Growth Factor 21 (FGF21) Associated with Visceral Adiposity Leads to Insulin Resistance: The Core Defect in Diabetes Mellitus.. Curr Diabetes Rev 21(5):e260424229342 PMID: 38676505
- 8. Guthrie G et al.. 2022. Fibroblast growth factor 15/19 expression, regulation, and function: An overview.. Mol Cell Endocrinol 548:111617 PMID: 35301051
